2023-08-012024-07-312024-07-31false14601231MYPHARM LTD2025-04-29falseiso4217:GBPxbrli:pure146012312023-08-01146012312024-07-31146012312023-08-012024-07-31146012312023-01-18146012312023-07-31146012312023-01-182023-07-3114601231bus:SmallEntities2023-08-012024-07-3114601231bus:AuditExempt-NoAccountantsReport2023-08-012024-07-3114601231bus:FullAccounts2023-08-012024-07-3114601231bus:PrivateLimitedCompanyLtd2023-08-012024-07-3114601231core:WithinOneYear2024-07-3114601231core:AfterOneYear2024-07-3114601231core:WithinOneYear2023-07-3114601231core:AfterOneYear2023-07-3114601231core:ShareCapital2024-07-3114601231core:SharePremium2024-07-3114601231core:RevaluationReserve2024-07-3114601231core:OtherReservesSubtotal2024-07-3114601231core:RetainedEarningsAccumulatedLosses2024-07-3114601231core:ShareCapital2023-07-3114601231core:SharePremium2023-07-3114601231core:RevaluationReserve2023-07-3114601231core:OtherReservesSubtotal2023-07-3114601231core:RetainedEarningsAccumulatedLosses2023-07-3114601231core:LandBuildings2024-07-3114601231core:PlantMachinery2024-07-3114601231core:Vehicles2024-07-3114601231core:FurnitureFittings2024-07-3114601231core:OfficeEquipment2024-07-3114601231core:NetGoodwill2024-07-3114601231core:IntangibleAssetsOtherThanGoodwill2024-07-3114601231core:ListedExchangeTraded2024-07-3114601231core:UnlistedNon-exchangeTraded2024-07-3114601231core:LandBuildings2023-07-3114601231core:PlantMachinery2023-07-3114601231core:Vehicles2023-07-3114601231core:FurnitureFittings2023-07-3114601231core:OfficeEquipment2023-07-3114601231core:NetGoodwill2023-07-3114601231core:IntangibleAssetsOtherThanGoodwill2023-07-3114601231core:ListedExchangeTraded2023-07-3114601231core:UnlistedNon-exchangeTraded2023-07-3114601231core:LandBuildings2023-08-012024-07-3114601231core:PlantMachinery2023-08-012024-07-3114601231core:Vehicles2023-08-012024-07-3114601231core:FurnitureFittings2023-08-012024-07-3114601231core:OfficeEquipment2023-08-012024-07-3114601231core:NetGoodwill2023-08-012024-07-3114601231core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3114601231core:ListedExchangeTraded2023-08-012024-07-3114601231core:UnlistedNon-exchangeTraded2023-08-012024-07-3114601231core:MoreThanFiveYears2023-08-012024-07-3114601231core:Non-currentFinancialInstruments2024-07-3114601231core:Non-currentFinancialInstruments2023-07-3114601231dpl:CostSales2023-08-012024-07-3114601231dpl:DistributionCosts2023-08-012024-07-3114601231core:LandBuildings2023-08-012024-07-3114601231core:PlantMachinery2023-08-012024-07-3114601231core:Vehicles2023-08-012024-07-3114601231core:FurnitureFittings2023-08-012024-07-3114601231core:OfficeEquipment2023-08-012024-07-3114601231dpl:AdministrativeExpenses2023-08-012024-07-3114601231core:NetGoodwill2023-08-012024-07-3114601231core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3114601231dpl:GroupUndertakings2023-08-012024-07-3114601231dpl:ParticipatingInterests2023-08-012024-07-3114601231dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3114601231core:ListedExchangeTraded2023-08-012024-07-3114601231dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3114601231core:UnlistedNon-exchangeTraded2023-08-012024-07-3114601231dpl:CostSales2023-01-182023-07-3114601231dpl:DistributionCosts2023-01-182023-07-3114601231core:LandBuildings2023-01-182023-07-3114601231core:PlantMachinery2023-01-182023-07-3114601231core:Vehicles2023-01-182023-07-3114601231core:FurnitureFittings2023-01-182023-07-3114601231core:OfficeEquipment2023-01-182023-07-3114601231dpl:AdministrativeExpenses2023-01-182023-07-3114601231core:NetGoodwill2023-01-182023-07-3114601231core:IntangibleAssetsOtherThanGoodwill2023-01-182023-07-3114601231dpl:GroupUndertakings2023-01-182023-07-3114601231dpl:ParticipatingInterests2023-01-182023-07-3114601231dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-182023-07-3114601231core:ListedExchangeTraded2023-01-182023-07-3114601231dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-182023-07-3114601231core:UnlistedNon-exchangeTraded2023-01-182023-07-3114601231core:NetGoodwill2024-07-3114601231core:IntangibleAssetsOtherThanGoodwill2024-07-3114601231core:LandBuildings2024-07-3114601231core:PlantMachinery2024-07-3114601231core:Vehicles2024-07-3114601231core:FurnitureFittings2024-07-3114601231core:OfficeEquipment2024-07-3114601231core:AfterOneYear2024-07-3114601231core:WithinOneYear2024-07-3114601231core:ListedExchangeTraded2024-07-3114601231core:UnlistedNon-exchangeTraded2024-07-3114601231core:ShareCapital2024-07-3114601231core:SharePremium2024-07-3114601231core:RevaluationReserve2024-07-3114601231core:OtherReservesSubtotal2024-07-3114601231core:RetainedEarningsAccumulatedLosses2024-07-3114601231core:NetGoodwill2023-07-3114601231core:IntangibleAssetsOtherThanGoodwill2023-07-3114601231core:LandBuildings2023-07-3114601231core:PlantMachinery2023-07-3114601231core:Vehicles2023-07-3114601231core:FurnitureFittings2023-07-3114601231core:OfficeEquipment2023-07-3114601231core:AfterOneYear2023-07-3114601231core:WithinOneYear2023-07-3114601231core:ListedExchangeTraded2023-07-3114601231core:UnlistedNon-exchangeTraded2023-07-3114601231core:ShareCapital2023-07-3114601231core:SharePremium2023-07-3114601231core:RevaluationReserve2023-07-3114601231core:OtherReservesSubtotal2023-07-3114601231core:RetainedEarningsAccumulatedLosses2023-07-3114601231core:NetGoodwill2023-01-1814601231core:IntangibleAssetsOtherThanGoodwill2023-01-1814601231core:LandBuildings2023-01-1814601231core:PlantMachinery2023-01-1814601231core:Vehicles2023-01-1814601231core:FurnitureFittings2023-01-1814601231core:OfficeEquipment2023-01-1814601231core:AfterOneYear2023-01-1814601231core:WithinOneYear2023-01-1814601231core:ListedExchangeTraded2023-01-1814601231core:UnlistedNon-exchangeTraded2023-01-1814601231core:ShareCapital2023-01-1814601231core:SharePremium2023-01-1814601231core:RevaluationReserve2023-01-1814601231core:OtherReservesSubtotal2023-01-1814601231core:RetainedEarningsAccumulatedLosses2023-01-1814601231core:AfterOneYear2023-08-012024-07-3114601231core:WithinOneYear2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:CostValuation2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3114601231core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3114601231core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3114601231core:Non-currentFinancialInstrumentscore:CostValuation2023-07-3114601231core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-3114601231core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-3114601231bus:Director12023-08-012024-07-3114601231core:FurnitureFittingsToolsEquipment2023-08-012024-07-3114601231core:FurnitureFittingsToolsEquipment2024-07-3114601231core:FurnitureFittingsToolsEquipment2023-07-31

MYPHARM LTD

Registered Number
14601231
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2024

MYPHARM LTD
Company Information
for the year from 1 August 2023 to 31 July 2024

Director

TANVEER, Muhammad

Registered Address

Bristol Pharmacy The Whitchurch Health Centre
Armada Road
Bristol
BS14 0SU

Registered Number

14601231 (England and Wales)
MYPHARM LTD
Balance Sheet as at
31 July 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets3478,780-
Tangible assets453,813-
532,593-
Current assets
Stocks579,130-
Debtors6341,468100
Cash at bank and on hand70,908-
491,506100
Creditors amounts falling due within one year7(1,025,050)-
Net current assets (liabilities)(533,544)100
Total assets less current liabilities(951)100
Net assets(951)100
Capital and reserves
Called up share capital100100
Profit and loss account(1,051)-
Shareholders' funds(951)100
The financial statements were approved and authorised for issue by the Director on 29 April 2025, and are signed on its behalf by:
TANVEER, Muhammad
Director
Registered Company No. 14601231
MYPHARM LTD
Notes to the Financial Statements
for the year ended 31 July 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Intangible assets
Goodwill, being the amount paid in connection with the acquisition of the business in 2023, is being amortised evenly over its estimated useful life of 10 years.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Fixtures and fittings25
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20242023
Average number of employees during the year110
3.Intangible assets

Other

Total

££
Cost or valuation
Additions531,977531,977
At 31 July 24531,977531,977
Amortisation and impairment
Charge for year53,19753,197
At 31 July 2453,19753,197
Net book value
At 31 July 24478,780478,780
At 31 July 23--
4.Tangible fixed assets

Fixtures & fittings

Total

££
Cost or valuation
Additions61,50061,500
At 31 July 2461,50061,500
Depreciation and impairment
Charge for year7,6877,687
At 31 July 247,6877,687
Net book value
At 31 July 2453,81353,813
At 31 July 23--
5.Stocks

2024

2023

££
Finished goods79,130-
Total79,130-
6.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables255,293-
Other debtors79,354100
Prepayments and accrued income6,821-
Total341,468100
7.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables180,154-
Taxation and social security8,243-
Payments received on account114,006-
Other creditors718,147-
Accrued liabilities and deferred income4,500-
Total1,025,050-